Le Lézard
Classified in: Health, Science and technology
Subjects: TRI, FDA

FDA Accepts Clinical Research Plan to Explore Senzer's Inhaler for Cancer Patients


LONDON, April 25, 2018 /PRNewswire/ --

The US Food and Drug Administration have accepted an application for a clinical development study on Dronabinol Inhalation using Senzer's unique breath-actuated inhaler, progressing the Company's US partner, INSYS Therapeutics, on its path for approval of the device as an innovative approach to help cancer patients, Senzer said (today).

INSYS, a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, said it had received notification that the FDA had accepted its filing for an Investigational New Drug for Dronabinol Inhalation. The approval means the clinical programme will now commence to explore chemotherapy-induced nausea and vomiting in adult cancer patients, whose response to conventional antiemetics has been sub-optimal. Researchers will also look at anorexia associated with weight loss in patients with AIDS under the IND application, and have plans to later expand the programme into anorexia in cancer and agitation in Alzheimer's disease.

"We are very excited that this milestone of IND acceptance has been achieved, and now look forward to working closely with the INSYS team on executing the clinical development programme," Senzer CEO Alex Hearn said. "Our novel device offers cancer patients a safe and effective means to reduce many of the negative and distressing effects of their treatment, and we look forward to generating the data to validate this approach."

INSYS are developing a pharmaceutical version of Dronabinol, a cannabinoid already approved by the FDA for chemotherapy-induced nausea and vomiting. The programme will aim to validate how this can be delivered through Senzer's proprietary inhaler, which offers an innovative way of ensuring a high uptake of pharmaceutical actives within a patient. Senzer says the handheld disposable device offers significant advantages over other delivery means, such as oral or IV.

"Senzer's proprietary inhalation technology involves no heat or combustion to deliver the therapeutic molecule to the distal lung, an important attribute in connection with Dronabinol, which requires an ambient temperature to maintain molecular stability," explained Venkat Goskonda, Senior Vice President of R&D for INSYS Therapeutics. "Our partner's hand-held device is actuated by the user's inhalation, obviating the need for the hand-breath coordination that is required with traditional metered-dose inhalers."


These press releases may also interest you

at 07:00
Palantir Technologies Inc. today announced that it was selected by the Defense Information Systems Agency (DISA) to deliver an Electromagnetic Battle Management - Joint Decision Support (EMBM-J DS) Prototype. This effort will provide the Department...

at 06:30
The Actuators market is estimated at USD 67.7 billion in 2024 and is projected to reach USD 94.8 billion by 2029, at a CAGR of 7.0 % from 2024 to 2029 according to a new report by MarketsandMarketstm. The growth can be attributed to growing...

at 06:13
JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") , one of the largest and most innovative solar module manufacturers in the world, today announced that since March 20, 2024, the Company has repurchased 788,178 American depositary shares...

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:02
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major...

at 06:00
G-P (Globalization Partners), the recognized leader in the global employment market, and standard bearer for industry compliance, today announced it was awarded 50 leader badges in G2's 2024 Spring Report, including Employer of Record Leader, Global...



News published on and distributed by: